A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers
The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Abstract
Even though 85% of adults drink caffeinated beverages daily, very limited studies on plasma caffeine concentration in the US population have been published. Smoking induces cytochrome P450 1A2 (CYP1A2), which is the main enzyme involved in caffeine metabolism. The current naturalistic pilot study explores plasma caffeine concentrations in a US sample, and presents a mathematical model of the relationship between caffeine intake and plasma concentrations for smokers and nonsmokers. Caffeine intake and average plasma caffeine concentrations from morning (7:30-9:30 a.m.) and afternoon (2:00-4:00 p.m.) samples were studied in 69 volunteers (21 smokers and 48 nonsmokers). The mean caffeine intake obtained from caffeinated beverages was 3.02 mg/kg/day, which is similar to the intake in the US population. Almost all subjects in the present sample (99%; 95% confidence interval [CI]: 96-100) had detectable plasma caffeine concentrations. Smokers had significantly higher caffeine intake than nonsmokers. The ratio of concentration/dose of caffeine from caffeinated beverages was approximately four-fold higher in nonsmokers (1.33 kgxday/l) than in smokers (0.29 kgxday/l). According to the model, the median plasma caffeine concentration was two- to three-fold higher in nonsmokers for each level of caffeine intake. Our model improves our understanding of the interactions between caffeine and smoking. Additional studies are needed to replicate the model. This model may help epidemiologists t…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The observed plasma concentration of caffeine in mice is consistent with the plasma concentration in humans (3.2 mg/l, 16 μM) drinking 2–5 cups of coffee per day (de Leon et al., 2003).”
From ATR–Chk1 Pathway Inhibition Promotes Apoptosis after UV Treatment in Primary Human Keratinocytes: Potential Basis for the UV Protective Effects of Caffeine (2009) · cites this paper as de Leon et al., 2003
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
An Introduction to the Bootstrap.
Buckland, S. T., Efron, B., & Tibshirani, R. J. (1994) · Biometrics · doi:10.2307/2532810 · Cited by 3,103
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Barone, J. J., & Roberts, H. R. (1996) · Food and Chemical Toxicology · doi:10.1016/0278-6915(95)00093-3 · Cited by 705 · cited 1×
“In the US, 85% of adults drink coffee, tea or caffeinated sodas daily, with an average intake of 200 mg/ day or 3 mg/kg/day (Barone and Roberts, 1996).”
Clinical Pharmacology of Caffeine
Benowitz, N. L. (1990) · Annual Review of Medicine · doi:10.1146/annurev.me.41.020190.001425 · Cited by 420 · cited 1×
“Surpris- ingly, US studies of plasma caffeine concentrations are very limited (e.g., one study on bus drivers, Sharp and Benowitz, 1990).”
BackgroundNakajima, M., Yokoi, T., Mizutani, M., Kinoshitah, M., Funayama, M., & Kamataki, T. (1999) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022352 · Cited by 346
Chou, W. H., Yan, F.-X., de Leon, J., Barnhill, J., Rogers, T., Cronin, M., Pho, M., Xiao, V., Ryder, T. B., Liu, W. W., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00019 · Cited by 226
Self-citationChen, S., Chou, W.-H., Blouin, R. A., Mao, Z., Humphries, L. L., Meek, Q. C., Neill, J. R., Martin, W. L., Hays, L. R., & Wedlund, P. J. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90148-4 · Cited by 150
Drug interactions with newer antidepressants: role of human cytochromes P450.
Greenblatt, D. J., Moltke, L. L., Harmatz, J. S., & Shader, R. I. (1998) · PubMed · Cited by 141
Cited by
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de Leon, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 351
Drug interactions with smoking
Kroon, L. A. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060414 · Cited by 345
Caffeine Use in Sports, Pharmacokinetics in Man, and Cellular Mechanisms of Action
Magkos, F., & Kavouras, S. A. (2005) · Critical Reviews in Food Science and Nutrition · doi:10.1080/1040-830491379245 · Cited by 344
“[ 147 ] On the other hand, smoking cessation has been shown to lead to significant (> 250%) increases in plasma caffeine concentration within 12 wk, at similar levels of caffeine intake; this exaggerated response persisted for up to 6 mo despite a 25% decrease in caffeine consumption,[ 148 ] clearly reflecting a slowi…”
BackgroundKang, S. S., Han, K.-S., Ku, B. M., Lee, Y. K., Hong, J., Shin, H. Y., Almonte, A. G., Woo, D. H., Brat, D. J., Hwang, E. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2886 · Cited by 197
“was approximately the same concentration in people drinking two to five cups of coffee per day (23).”
Manfredsdottir, V., Víkingsdóttir, T., JÓNSSON, T., Geirsson, Á. J., Kjartansson, Ó., Heimisdóttir, M., Sigurdardottir, S. L., Valdimarsson, H., & Víkingsson, A. (2006) · Rheumatology · doi:10.1093/rheumatology/kei240 · Cited by 176
“Smoking induces cytochrome-P450 activity and smokers may therefore require a caffeine intake four times higher to obtain the same plasma caffeine level as non-smokers [26].”
Background
Metadata
- Authors
- de Leon, J., Diaz, F. J., Rogers, T., Browne, D., Dinsmore, L., Ghosheh, O. H., Dwoskin, L. P., & Crooks, P. A.
- Affiliations
- University of Kentucky (US)
- ORCID
- Crooks, Peter A
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2003-02
- Volume
- 27
- Issue
- 1
- Pages
- 165-171
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2073650362
- Cited by
- 77
- References
- 20
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 3 · 2012: 7
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01da008656-03, 5r29mh051380-05)
- National Institute of Mental Health (MH-51380)
- National Institute on Drug Abuse (DA-08656, DA-00399, K02DA000399)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- plasma caffeine concentration, caffeine consumption, smoking, CYP1A2, caffeine metabolism, mathematical model, smokers versus non-smokers
- MeSH terms
- Adult, Central Nervous System Stimulants, Caffeine, Female, Humans, Male, Middle Aged, Smoking, United States, Epidemiologic Studies, Cytochrome P-450 CYP1A2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. https://app.cochat.ai/papers/10.1016/s0278-5846(02)00348-2
- The paper
- de Leon, J., Diaz, F. J., Rogers, T., Browne, D., Dinsmore, L., Ghosheh, O. H., Dwoskin, L. P., & Crooks, P. A. (2003). A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. Progress in Neuro-Psychopharmacology and Biological Psychiatry. https://doi.org/10.1016/s0278-5846(02)00348-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.